---
figid: PMC5823664__oncotarget-09-9540-g001
figtitle: 'Glioblastoma: new therapeutic strategies to address cellular and genomic
  complexity'
organisms:
- Mus musculus
- Rattus norvegicus
- Enterovirus C
- Human rhinovirus sp.
- Homo sapiens
- Elephas maximus
organisms_ner:
- Mus musculus
- Homo sapiens
- Rattus norvegicus
- Drosophila melanogaster
pmcid: PMC5823664
filename: oncotarget-09-9540-g001.jpg
figlink: /pmc/articles/PMC5823664/figure/F1/
number: F1
caption: DNA sequence alterations including gene mutation/deletion/amplification,
  gene fusion, and epigenetic modification as well as regulatory mutation result in
  activation of multiple signaling pathways, which contribute to GBM development.
  Traditional targeted therapies are using inhibitors targeting the signaling pathways.
  However, novel therapeutic strategies are signaling pathway independent. Gene therapy,
  immunotherapy, stem cell therapy and CRISPR/Cas9 technology aim to deliver a gene
  to produce toxicity to cancer cells or cause cancer cell apoptosis, enhance host
  immune responses, and correct the mutated genome, which consequently will reduce/cure
  GBM.
papertitle: 'Glioblastoma: new therapeutic strategies to address cellular and genomic
  complexity.'
reftext: Xue Cai, et al. Oncotarget. 2018 Feb 6;9(10):9540-9554.
year: '2018'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.6597019
figid_alias: PMC5823664__F1
figtype: Figure
redirect_from: /figures/PMC5823664__F1
ndex: db03ee75-df10-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5823664__oncotarget-09-9540-g001.html
  '@type': Dataset
  description: DNA sequence alterations including gene mutation/deletion/amplification,
    gene fusion, and epigenetic modification as well as regulatory mutation result
    in activation of multiple signaling pathways, which contribute to GBM development.
    Traditional targeted therapies are using inhibitors targeting the signaling pathways.
    However, novel therapeutic strategies are signaling pathway independent. Gene
    therapy, immunotherapy, stem cell therapy and CRISPR/Cas9 technology aim to deliver
    a gene to produce toxicity to cancer cells or cause cancer cell apoptosis, enhance
    host immune responses, and correct the mutated genome, which consequently will
    reduce/cure GBM.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Akt1
  - ras
  - Hras
  - Kras
  - Rem1
  - Pik3r1
  - Mtor
  - Mdk
  - Zhx2
  - Trp53
  - Tgfb1
  - Ltbp1
  - AKT1
  - AKT2
  - AKT3
  - KRAS
  - HRAS
  - NRAS
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - MTOR
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - WNT1
  - WNT2
  - WNT2B
  - WNT3
  - WNT3A
  - WNT4
  - WNT6
  - WNT7A
  - WNT7B
  - WNT8A
  - WNT8B
  - WNT9A
  - WNT9B
  - WNT10A
  - WNT10B
  - WNT11
  - WNT16
  - WNT5A
  - WNT5B
  - TP53
  - TP63
  - TP73
  - TGFB1
  - TGFB2
  - TGFB3
  - Pik3cg
  - Wnt2
  - Tp53
  - Akt
  - Ras64B
  - Ras85D
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Tor
  - Dsor1
  - Mtk
  - MKP-4
  - p38b
  - rl
  - Raf
  - Wnt5
  - Wnt4
  - wg
  - p53
  - betaTub60D
  - hth
  - dpp
  - gbb
  - put
  - mav
  - rb
  - CG1136
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
